Men with high testing PCPs, in comparison to low testing PCPs, had higher rates of receiving PSA tests (82.7 % vs. 57.7 %, p < 0.001), prostate biopsies (2.4 % vs. 2.1 %, p = 0.022), ultrasound (3.4 % vs. 2.9 %, p = 0.002) and radiation treatment for prostate cancer (0.7 % vs. 0.5 %, p = 0.013). The gene discussed is KLK3; the disease is prostate carcinoma.